CN1230161C - 柿叶提取物和它的制备方法及用途 - Google Patents
柿叶提取物和它的制备方法及用途 Download PDFInfo
- Publication number
- CN1230161C CN1230161C CN 200310112425 CN200310112425A CN1230161C CN 1230161 C CN1230161 C CN 1230161C CN 200310112425 CN200310112425 CN 200310112425 CN 200310112425 A CN200310112425 A CN 200310112425A CN 1230161 C CN1230161 C CN 1230161C
- Authority
- CN
- China
- Prior art keywords
- extract
- folium kaki
- ethanol
- group
- fldk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 100
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 235000011511 Diospyros Nutrition 0.000 title abstract description 12
- 244000055850 Diospyros virginiana Species 0.000 title 1
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 70
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 25
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920005989 resin Polymers 0.000 claims abstract description 19
- 239000011347 resin Substances 0.000 claims abstract description 19
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 claims abstract description 15
- 201000005851 intracranial arteriosclerosis Diseases 0.000 claims abstract description 15
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 14
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 14
- 208000006011 Stroke Diseases 0.000 claims abstract description 14
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 12
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000005875 quercetin Nutrition 0.000 claims abstract description 12
- 229960001285 quercetin Drugs 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 235000008597 Diospyros kaki Nutrition 0.000 claims description 84
- 229930003944 flavone Natural products 0.000 claims description 23
- 235000011949 flavones Nutrition 0.000 claims description 23
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 20
- 150000002213 flavones Chemical class 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 10
- 235000008777 kaempferol Nutrition 0.000 claims description 10
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 10
- 210000000653 nervous system Anatomy 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 241000792913 Ebenaceae Species 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 abstract description 21
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 241000723267 Diospyros Species 0.000 abstract description 3
- 229930003935 flavonoid Natural products 0.000 abstract description 2
- 150000002215 flavonoids Chemical class 0.000 abstract description 2
- 235000017173 flavonoids Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 1
- 230000007658 neurological function Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 66
- 230000000694 effects Effects 0.000 description 39
- 208000024891 symptom Diseases 0.000 description 34
- 208000028867 ischemia Diseases 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 206010008118 cerebral infarction Diseases 0.000 description 17
- 230000001681 protective effect Effects 0.000 description 17
- 208000002173 dizziness Diseases 0.000 description 16
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 16
- 201000006474 Brain Ischemia Diseases 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 230000000302 ischemic effect Effects 0.000 description 13
- 206010008120 Cerebral ischaemia Diseases 0.000 description 12
- 230000006399 behavior Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 206010019233 Headaches Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 231100000869 headache Toxicity 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 230000010410 reperfusion Effects 0.000 description 10
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 239000010225 buchang naoxintong Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 206010022437 insomnia Diseases 0.000 description 8
- 244000194101 Ginkgo biloba Species 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000005779 cell damage Effects 0.000 description 7
- 208000037887 cell injury Diseases 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 150000002212 flavone derivatives Chemical class 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 210000003061 neural cell Anatomy 0.000 description 7
- 210000004129 prosencephalon Anatomy 0.000 description 7
- 210000002763 pyramidal cell Anatomy 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 201000004810 Vascular dementia Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 108700017511 rat Y acceptor Proteins 0.000 description 6
- 206010061876 Obstruction Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 229960003980 galantamine Drugs 0.000 description 5
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 5
- 206010034754 petechiae Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010013952 Dysphonia Diseases 0.000 description 4
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 210000004744 fore-foot Anatomy 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 210000003701 histiocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N Kaempferide Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 201000008247 brain infarction Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- -1 flavone glycoside Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010054196 Affect lability Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010058483 Nuchal rigidity Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- 239000009335 naoxintong Substances 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000005036 potential barrier Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- HDDDNIUXSFCGMB-UHFFFAOYSA-N quercetin 3-galactoside Natural products OCC1OC(OC2=C(Oc3ccc(O)c(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C(O)C1O HDDDNIUXSFCGMB-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Abstract
Description
组别 | 动物数 | 锥体神经细胞密度(/mm) |
正常对照 | 8 | 185.5±17.1 |
生理盐水 | 8 | 7.5±3.4** |
FLDK低10mg/kg | 8 | 42.3±21.6### |
FLDK中40mg/kg | 8 | 81.5±18.1### |
FLDK高80mg/Kg | 8 | 85.7±18.7### |
天保宁100mg/kg | 8 | 51.7±16.0### |
组别 | 药物剂量 | 动物数/(n) | 缺血后不同时间的行为评分(分) | |||
12h | 24h | 48h | 72h | |||
假手术组 | 6 | 0 | ||||
生理盐水 | 5.0ml/kg | 8 | 3.0…… | 2.5 | 2.38 | 2.00 |
柿叶提取物低剂量组 | 20mg/kg | 7 | 3.14 | 3.14 | 1.86 | 1.57 |
柿叶提取物中剂量组 | 40mg/kg | 9 | 1.11** | 1.11** | 1.00** | 0.88** |
柿叶提取物高剂量组 | 80mg/kg | 8 | 1.25** | 1.25** | 1.00** | 0.75** |
银可络组 | 40mg/kg | 10 | 1.00* | 1.00** | 0.70** | 0.50** |
组别 | 药物剂量 | 动物数(n) | 脑水肿面积 | 保护率(%) |
假手术组 | 6 | -1.80±6.49 | ||
生理盐水对照组 | 5.0ml/kg | 8 | 26.38±11.90## | |
柿叶提取物小剂量组 | 20mg/kg | 7 | 19.86±13.02** | 21.4 |
柿叶提取物中剂量组 | 40mg/kg | 9 | 14.89±9.93** | 43.6 |
柿叶提取物大剂量组 | 80mg/kg | 8 | 10.50±5.66*** | 60.2 |
银可络组 | 40.0mg/kg | 10 | 13.80±9.69*** | 47.7 |
组别 | 药物剂量 | 动物数(n) | 脑梗死面积(%) | 保护率(%) |
假手术组 | 6 | 0 | ||
生理盐水对照组 | 5.0ml/kg | 8 | 34.93±5.67 | |
柿叶提取物低剂量组 | 20mg/kg | 7 | 27.68±6.61* | 20.8 |
柿叶提取物中剂量组 | 40mg/kg | 9 | 20.15±4.53** | 42.3 |
柿叶提取物高剂量组 | 80mg/Kg | 8 | 14.53±4.48** | 58.6 |
银可络组 | 40.0mg/kg | 10 | 18.16±4.72** | 48.0 |
组别 | 剂量mg/kg | 第1天 | 第2天 | 第3天 | 第4天 |
N组 | 0 | 0.55±0.23 | 0.73±0.25 | 0.91±0.17 | 0.98±0.12 |
M组 | 0 | 0.50±0.29 | 0.63±0.26 | 0.81±0.19 | 0.85±0.11# |
FLDK低 | 20 | 0.52±0.27 | 0.68±0.25 | 0.87±0.22 | 0.94±0.11* |
FLDK中 | 40 | 0.54±0.25 | 0.69±0.27 | 0.89±0.18 | 0.98±0.11** |
FLDK高 | 80 | 0.53±0.28 | 0.72±0.24 | 0.91±0.12* | 0.99±0.09** |
加兰他敏 | 60 | 0.58±0.29 | 0.73±0.25 | 0.90±0.10 | 0.98±0.10** |
组别 | 剂量mg/kg | 动物数n | 潜伏期(秒) |
N组 | 0 | 10 | 3.8±2.4 |
M组 | 0 | 10 | 7.5±3.9# |
FLDK低 | 20 | 10 | 5.1±3.3 |
FLDK中 | 40 | 10 | 4.4±2.5* |
FLDK高 | 80 | 10 | 3.6±2.7** |
加兰他敏 | 60 | 10 | 3.8±2.5** |
组别 | 启动方式 | 逃避速度 | 逃避终点 |
N | 直接矢往灯光处 | 小跑 | 安全臂灯源处 |
M | 剧烈跳蹦数次打转数圈后再矢往灯光处 | 疾跑 | 安全臂近心端,敲击迷宫仪仅驱使少数大鼠靠近灯源处 |
FLDK低 | 和M组相似,但跳蹦剧烈程度、但跳蹦剧 | 疾跑 | 安全臂近心端,敲击迷宫仪 |
烈程度、次数和打转圈数明显减少 | 后大多数立刻小跑至灯源处 | ||
FLDK中 | 直接矢往灯光处 | 疾跑 | 安全臂灯源处 |
FLDK高 | 直接矢往灯光处 | 疾跑 | 安全臂灯源处 |
加兰他敏 | 直接矢往灯光处 | 疾跑 | 安全臂灯源处 |
病种 | 例数 | 显效 | 有效 | 无效 | 有效率 | |
脑动脉硬化 | 38 | 12 | 22 | 4 | 89.47% | |
劳心累绞型痛 | I | 5 | 1 | 3 | 1 | 80.00% |
II | 15 | 8 | 5 | 2 | 86.67% | |
II | 2 | 0 | 1 | 1 | 50% | |
共计 | 60 | 21 | 31 | 8 | 86.67% |
病种 | 收缩压(mmHg) | 舒张压(mmHg) | ||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |
冠心病 | 162.36+16.21 | 131.28+13.11** | 106.21+10.12 | 80.36+9.67* |
脑动脉硬化 | 168.79+12.42 | 142.13+11.39** | 95.79+15.13 | 89.32+11.24 |
病种 | 胆固醇(mg/dl) | 甘油三酯(mg/dl) | ||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |
冠心病 | 189.91+31.61 | 175.23+26.13 | 165.25+19.52 | 142.16+18.32* |
脑动脉硬化 | 246.51+24.18 | 205.18+21.32** | 126.06+12.24 | 80.35+10.23** |
头晕头痛 | 胸痛 | 眩晕 | 失眠 | 情绪不稳 | 面色暗红黑 | 舌质暗或有瘀斑 | |
总例数 | 48 | 12 | 40 | 41 | 52 | 32 | 55 |
有效数 | 45 | 10 | 36 | 36 | 45 | 17 | 42 |
有效率% | 93.75 | 83.33 | 90.0 | 90.80 | 86.54 | 53.13 | 76.36 |
药物组 | n | 治疗前 | 治疗后 | P |
FLDK | 30 | 12.45±5.42 | 19.05±6.09 | <0.05 |
步长脑心通 | 30 | 12.58±5.38 | 18.79±6.16 | <0.05 |
量表名 | n | 治疗前 | 治疗后 | P |
FLDK | 30 | 12.95±5.62 | 19.85±6.19 | <0.05 |
步长脑心通 | 30 | 12.98±5.78 | 19.62±6.36 | <0.05 |
主要症状 | 药物 | n | 治疗前 | 治疗后 | P |
神情呆滞 | FLDK步长脑心通 | 30 | 3.15±0.543.18±0.53 | 2.31±0.802.30±0.81 | <0.01<0.01 |
语言不利 | FLDK步长脑心通 | 28 | 3.33±0.653.31±0.65 | 2.28±0.932.30±0.95 | <0.01<0.01 |
善忘不寐 | FLDK步长脑心通 | 29 | 3.83±0.563.61±0.56 | 1.31±0.951.33±0.93 | <0.01<0.01 |
头晕头痛 | FLDK步长脑心通 | 30 | 3.91±0.853.76±0.85 | 1.31±0.851.30±0.83 | <0.01<0.01 |
舌质瘀点 | FLDK步长脑心通 | 30 | 2.03±0.422.05±0.42 | 1.28±0.641.29±0.61 | <0.01<0.01 |
病名 | n | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) | ||||
例 | 率(%) | 例 | 率(%) | 例 | 率(%) | 例 | 率(%) |
FLDK | 30 | 0 | 0 | 4 | 16.7 | 18 | 60.0 | 8 | 26.7 | 73.4 |
步长脑心通 | 30 | 0 | 0 | 4 | 13.3 | 17 | 56.7 | 9 | 30.0 | 70.4 |
药物组 | n | 治疗前 | 治疗后 | P |
FLDK | 90 | 13.45±5.42 | 18.65±5.92 | <0.05 |
天保宁胶囊 | 90 | 12.98±5.78 | 19.72±5.86 | <0.05 |
量表名 | n | 治疗前 | 治疗后 | P |
FLDK | 90 | 5.85±3.34 | 10.30±4.30 | <0.01 |
天保宁胶囊 | 90 | 5.98±3.38 | 10.16±4.16 | <0.01 |
主要症状 | n | 治疗前 | 治疗后 | P |
神情呆滞 | 30 | 3.15±0.54 | 2.31±0.85 | <0.01 |
思考力障碍 | 25 | 3.28±0.64 | 2.25±0.78 | <0.05 |
判断力障碍 | 28 | 3.33±0.85 | 2.13±0.95 | <0.05 |
记忆力障碍 | 28 | 3.36±0.85 | 2.18±0.85 | <0.05 |
语言不利 | 28 | 3.31±0.65 | 2.23±0.98 | <0.01 |
失眠 | 30 | 3.83±0.56 | 1.30±0.85 | <0.01 |
烦躁、易怒、 | 30 | 3.56±0.53 | 1.520±0.85 | <0.01 |
舌质瘀点 | 30 | 2.13±0.40 | 1.18±0.62 | <0.01 |
病名 | n | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) | ||||
例 | 率(%) | 例 | 率(%) | 例 | 率(%) | 例 | 率(%) | |||
FLDK胶囊 | 30 | 0 | 0 | 4 | 16.7 | 16 | 53.3 | 10 | 30 | 70.0 |
天保宁胶囊 | 30 | 0 | 0 | 3 | 10.0 | 16 | 53.3 | 11 | 33.0 | 67.7 |
治疗前积分 | 治疗后积分 | p | |
意识 | 7.82±1.3 | 3.2±1.6 | <0.01 |
水平凝视功能 | 3.21±0.68 | 1.5±0.95 | <0.01 |
面瘫 | 2.45±0.65 | 0.89±0.65 | <0.01 |
言语 | 4.53±1.88 | 1.58±0.78 | <0.01 |
上肢肌力 | 5.12±1.21 | 2.13±0.89 | <0.01 |
手肌力 | 4.64±1.89 | 1.98±1.2 | <0.01 |
下肢肌力 | 4.87±1.98 | 2.21±1.32 | <0.01 |
步行能力 | 3.86±1.76 | 1.78±1.21 | <0.01 |
治疗前积分 | 治疗后积分 | p | |
神经状态 | 3.28±0.64 | 1.54±0.85 | <0.01 |
语言能力 | 2.98±0.75 | 1.18±0.65 | <0.01 |
上肢肩关节 | 3.53±0.68 | 1.55±0.91 | <0.01 |
上肢指关节 | 2.95±0.85 | 0.89±0.65 | <0.01 |
下肢髋关节 | 3.21±0.68 | 1.65±0.67 | <0.01 |
下肢趾关节 | 2.65±0.61 | 0.86±0.60 | <0.01 |
综合功能 | 2.89±0.68 | 0.89±0.60 | <0.01 |
主要症状 | n | 治疗前 | 治疗后 | P |
头晕目眩 | 28 | 2.35±0.56 | 1.01±0.75 | <0.01 |
头痛 | 22 | 2.63±0.56 | 0.63±0.65 | <0.01 |
颈项强急 | 30 | 2.15±0.54 | 2.31±0.80 | <0.01 |
肢体强急 | 25 | 2.03±0.46 | 1.28±0.64 | <0.01 |
肢体麻木 | 21 | 2.03±0.42 | 1.15±0.64 | <0.01 |
舌质 | 30 | 2.63±0.42 | 1.28±0.64 | <0.01 |
病名 | n | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) | ||||
例 | 率(%) | 例 | 率(%) | 例 | 率(%) | 例 | 率(%) | |||
FLDK | 30 | 0 | 0 | 15 | 50 | 11 | 36.67 | 4 | 13.33 | 86.67 |
样品序号 | E50 | 97号 | 96 | 98 |
槲皮素含量(%) | 8.3 | 13.6 | 11.5 | 13.9 |
山奈素含量(%) | 17.6 | 16.5 | 13.5 | 19.6 |
总黄酮含量(%) | 66.6 | 77.4 | 64.2 | 85.2 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310112425 CN1230161C (zh) | 2003-12-03 | 2003-12-03 | 柿叶提取物和它的制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310112425 CN1230161C (zh) | 2003-12-03 | 2003-12-03 | 柿叶提取物和它的制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1546014A CN1546014A (zh) | 2004-11-17 |
CN1230161C true CN1230161C (zh) | 2005-12-07 |
Family
ID=34336521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310112425 Expired - Lifetime CN1230161C (zh) | 2003-12-03 | 2003-12-03 | 柿叶提取物和它的制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1230161C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006241054A (ja) * | 2005-03-02 | 2006-09-14 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | 石蓮花の含有成分とその用途 |
CN101744863B (zh) * | 2010-01-29 | 2012-12-12 | 广州白云山和记黄埔中药有限公司 | 柿叶提取物制剂及其制备方法和用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100367970C (zh) * | 2005-01-24 | 2008-02-13 | 中国人民解放军第二军医大学 | 山奈酚衍生物用于制备防治痴呆药物的用途 |
CN101045076B (zh) * | 2006-03-27 | 2010-05-12 | 广州白云山和记黄埔中药有限公司 | 柿叶乙酸乙酯提取物用于预防和/或治疗糖脂代谢相关疾病 |
CN101194921B (zh) * | 2006-12-08 | 2011-12-21 | 广州白云山和记黄埔中药有限公司 | 柿叶黄酮提取物的用途 |
CN102068484B (zh) * | 2011-01-08 | 2012-05-23 | 桂林普兰德生物科技有限公司 | 从柿叶提取含量为85-98%的柿叶黄酮的方法 |
CN106187972B (zh) * | 2016-07-14 | 2018-02-06 | 时文春 | 一种从金缕梅中提取山奈酚和槲皮素的方法 |
CN106727868B (zh) * | 2016-12-26 | 2020-09-01 | 合肥智汇医药科技有限公司 | 一种柿叶提取物在制备防治老年痴呆的药物中的应用 |
CN110787207A (zh) * | 2019-12-21 | 2020-02-14 | 西安交通大学 | 柿叶黄酮提取物在制备药物中的应用 |
CN114224933B (zh) * | 2022-01-17 | 2023-01-24 | 广州思沛医药科技股份有限公司 | 柿叶黄酮提取物及其制备方法 |
-
2003
- 2003-12-03 CN CN 200310112425 patent/CN1230161C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006241054A (ja) * | 2005-03-02 | 2006-09-14 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | 石蓮花の含有成分とその用途 |
CN101744863B (zh) * | 2010-01-29 | 2012-12-12 | 广州白云山和记黄埔中药有限公司 | 柿叶提取物制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1546014A (zh) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101032560A (zh) | 一种治疗睡眠障碍的中药组合物及制备方法 | |
CN1230161C (zh) | 柿叶提取物和它的制备方法及用途 | |
CN101032580A (zh) | 一种治疗风湿性疾病的药物 | |
CN1883638A (zh) | 治疗抑郁症的复方药物及其制备方法 | |
CN1565553A (zh) | 治疗痛经的中药 | |
CN1403138A (zh) | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂及制备 | |
CN106421579B (zh) | 一种治疗疲劳的中药组合物及其制备方法 | |
CN100586465C (zh) | 治疗抑郁症的中药组合物及其制备方法 | |
CN1723936A (zh) | 一种抗抑郁症的中药及其制备方法 | |
CN1221280C (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1732921A (zh) | 藁本内酯在制备预防和治疗脑缺血性疾病的药物中的应用 | |
CN100339092C (zh) | 一种用于治疗中风的中药组合物及其制备方法和其用途 | |
CN1290566C (zh) | 治疗抑郁症的药物制剂及其制备方法 | |
CN1172711C (zh) | 治疗慢性结膜炎的中药制剂 | |
CN1182864C (zh) | 一种治疗血管性痴呆疾病的药物及其制备方法 | |
CN1526440A (zh) | 治疗肌肉萎缩肌无力-痿症的中药复方制剂及制备方法 | |
CN1290547C (zh) | 一种治疗和预防高血压的中药及其制备工艺 | |
CN1284589C (zh) | 一种治疗急性脑血管疾病的药物及其制备方法 | |
CN1903240A (zh) | 草本刺嫩芽的医药用途 | |
CN1250241C (zh) | 柿叶提取物在制备防治神经功能退化症药物中的应用 | |
CN1250278C (zh) | 治疗痴呆症和智力低下的口服药物 | |
CN1686302A (zh) | 一种治疗非酒精性单纯性脂肪肝的中药及其制备方法 | |
CN1712053A (zh) | 一种治疗妇科月经不调和痛经的药物及制备方法 | |
CN1209162C (zh) | 治疗痤疮、黄褐斑的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BAIYUNSHAN CHINESE HUTCHISON WHAMPOA LT Free format text: FORMER OWNER: BAIYUNSHAN PHARMACEUTICAL FACTORY OF TRADITIONAL CHINESE DRUG, BAIYUNSHAN PHARMA Effective date: 20060303 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060303 Address after: 510515, No. 389 Sha Mo Road, Baiyun District, Guangdong, Guangzhou Patentee after: HUTCHISON WHAMPOA GUANGZHOU BAIYUNSHAN CHINESE MEDICINE Co.,Ltd. Address before: 510515, No. 389 Sha Mo Road, Baiyun District, Guangdong, Guangzhou Patentee before: Guangzhou Baiyunshan Pharmaceutical Co.,Ltd. Guangzhou Baiyunshan traditional Chinese medicine factory |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051207 |